Watching Summit Therapeutics Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planSummit Therapeutics Inc.
www.smmttx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Summit Therapeutics announced updated overall survival analysis results from its Phase III HARMONi trial showing promising trends for ivonescimab combined with chemotherapy in treating EGFR-mutated advanced non-small cell lung cancer, with consistent results across western and Asian patient populations.
Key Takeaways
Phase III HARMONi trial data shows consistent overall survival trends for ivonescimab plus chemotherapy versus placebo in previously treated EGFR-mutated non-small cell lung cancer patients
Analysis includes data from both western and Asian patient populations, demonstrating broad applicability of the treatment approach
2 more takeaways
Related Filings (1)
1 more filing from Summit Therapeutics Inc. in the last 90 days
Filing Overview
What This Means
Summit Therapeutics Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.